Pricing and market access has fascinated us, ever since we initially met and cut our market access teeth whilst working for Cambridge Pharma/IMS, one of the first specialist market access consultancy in the mid noughties.
Market access was emerging into the mainstream of Pharma and it was obvious to us that successful navigation was going to be pivotal to companies and patients alike in the future. This was an area that was only going to get more complex as the years go by past.
After a number of years, we both ended up changing jobs, moving to Switzerland and working for separate pharma companies in Switzerland within their global and European market access teams.
During this time we commissioned multiple external market access agencies to support us in both pricing and market access strategy and implementation initiatives. This gave us a real flavour as to both the ‘good’ and ‘not so good’ consultancy approaches.
“The good”
The good being the ones that really understood the issue we were trying to address, had in-depth technical expertise, who could develop an approach that matched our budgets; who appreciated that business priorities / clinical development plans adapt and could modify their approach accordingly without additional bureaucracy!
“The bad”
The bad being those companies who did not provide sufficient senior input into projects, had exorbitant budgets, ended up telling us things we already knew or just regurgitating payer feedback without thinking of the strategy or implications for us as a pharmaceutical company.
Whilst we both enjoyed our time working within pharma, a combination of changes in personal circumstances, company re-organizations and politics, led us to think differently. We were still fascinated by pricing and market access and the need was growing exponentially. We began thinking that there must be a better way to add value to companies whilst ensuring that patients secured timely access to innovative treatments.
Over a couple of BD meetings (BD = beer drinking!), the concept of Remap (REimbursement, Market Access and Pricing) was born. Right from day 1, Paul and Graham outlined the principles of Remap:
Since that meeting in October 2014, we have stuck by these principles and ensure they are instilled across the Remap team.
Stemming from a background of life sciences, our team have extensive experience of pricing and market access and understand payer and HTA needs.
If you’re passionate about making a positive difference in others’ lives, have an entrepreneurial spirit, and possess a keen eye for detail, we’d love to hear from you.
Our dedicated CSR team have implemented several policies and programmes which support the wellbeing of our colleagues, the local community, and the environment.
Diversity, Equity and Inclusion is a big part of our company culture. We believe that by fostering an environment where every individual feels valued, respected, and included, we cultivate a culture of excellence.
I really enjoyed working with Remap Consulting and received powerful advice. A small company like ours needs to receive a flexible approach in order start with market access activities, and I am very happy to see you are as flexible as possible with us.
Remap Consulting’s pricing knowledge and support has been critical to the success of our new pricing team. Their combined experience has provided them with ‘real-world‘ knowledge that can support their recommendations. I highly recommend Remap Consulting and am delighted to continue my work with their pricing group.
